chemicals by some osteoarthritis patients is due to genetic differences
and whether the genetic differences increase the likelihood of
developing disease in multiple joints.
-- Publication in Nutrition on Inflammation Reduction from Botanical
Supplement: In September 2007, Interleukin Genetics reported results
published in the Journal Nutrition of a study finding that patients who
tested positive for at-risk IL-1 gene variations were more likely to
show a decrease in inflammation after botanical treatment than those
who tested negative for the IL-1 gene variations.
Conference Call and Webcast Information
Interleukin Genetics will host a live conference call and webcast today at 4:30 p.m. EDT. To access the live call, dial 877-440-5803 (domestic) or 719- 325-4900 (international). The live webcast will be available in the Investors section of the Company's website, http://www.ilgenetics.com.
Replay access of the teleconference will be available for two weeks following the call by dialing 719-457-0820 (domestic) or 888-203-1112 (international). The passcode for the replay is 3385694. The webcast will be archived following the call at http://www.ilgenetics.com.
Interleukin Genetics, Inc. (Amex: ILI) is a genetics-focused
personalized health company that develops preventive consumer products and
genetic tests for sale to the emerging personalized health market. Focused
on the future of health and medicine, Interleukin uses its leading genetics
research and scientific capabilities to develop an
|SOURCE Interleukin Genetics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved